References
- Naftolin F, Schneider H PG, Sturdee D W, for the Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004; 7: 333–337
- Phillips L S, Langer R D. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558–566
- MacLennan A H, Henderson V W, Paine B J, et al. Hormone therapy, timing of initiation and cognition in women older than 60 years: the REMEMBER pilot study. Menopause 2006; 13: 28–36
- Alexandersen P, Tankó L B, Bagger Y Z, et al. The long-term impact of 2–3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 2006; 9: 108–118
- Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006; 15: 35–44
- Hsia J, Langer R D, Manson J E, , for the Women' Health Initiative Investigators, et al. Conjugated equine estrogens and coronary disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
- Pines A, Sturdee D W, Birkhäuser M, for the International Menopause Society. Press Statement, February 13, 2006. More data on hormone therapy and coronary heart disease: comments on recent publications from the WHI and Nurses' Health Study. Climacteric 2006; 9: 75–76
- Naftolin F, Taylor H S, Karas R. Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004; 81: 1498–1501
- Salpeter S R. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?. Climacteric 2005; 8: 307–310
- Salpeter S R, Walsh J M, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791–804